Ersodetug Biosimilar - Research Grade

Human

INSR

>1mg/ml

IgG2 - kappa

CHO Cells

Insulin Biosimilar - Research Grade (ICH5607)

https://www.imgt.org/mAb-DB/

ICH3002

P06213

3643

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ersodetug (RZ358), a fully human IgG2-kappa monoclonal antibody directed against the human insulin receptor (INSR). The originator drug binds the insulin receptor allosterically to attenuate downstream insulin signaling and is in clinical development for hyperinsulinism-associated hypoglycemia; this research-grade version reproduces the antibody's target specificity without any therapeutic claim. Supplied for research use only (RUO), it is not the clinical drug and is not intended for human or veterinary use. The biosimilar is useful as a reference and benchmarking reagent for anti-INSR antibody workflows: positive/isotype-matched controls, receptor-binding and epitope-competition assays, characterization of insulin-receptor engagement, and preclinical mechanistic studies in cell-based systems. It is well suited to comparability, assay-development, and standard-curve work where a defined, consistent anti-INSR IgG2 is needed. Available at low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support scale-up, screening campaigns, and reproducible lot-to-lot performance. The insulin receptor (INSR, UniProt P06213) is a transmembrane receptor tyrosine kinase and the principal mediator of insulin action. It is synthesized as a proreceptor that is cleaved into alpha and beta subunits, assembling into a disulfide-linked (alpha-beta)2 homodimer; two splice isoforms (IR-A and IR-B) differ in exon 11 inclusion and ligand affinity. Insulin binding to the extracellular alpha subunits triggers a conformational change that activates the intracellular beta-subunit tyrosine kinase, driving autophosphorylation and recruitment of IRS proteins. This initiates the PI3K-AKT axis governing glucose uptake, glycogen and lipid synthesis, and the RAS-MAPK axis influencing growth. INSR is central to metabolic homeostasis in liver, muscle, and adipose tissue, and its dysregulation underlies insulin resistance, diabetes, and hyperinsulinemic hypoglycemia.

IR, Insulin receptor

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Ersodetug (anti-INSR) Biosimilar

Q: Is the Ersodetug biosimilar available in bulk or gram quantities?

A: Yes — the Ersodetug biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Ersodetug suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ersodetug biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ersodetug that binds INSR.